Business
Xenetic Biosciences, Inc. Reports Full Year 2024 Financial Results
Encouraging preclinical data supporting the use of DNase-based technology to target NETosis and address difficult to treat cancersStrategic focus on
About this update from Xenetic Biosciences, Inc.
[{"type":"text","content":"Encouraging preclinical data supporting the use of DNase-based technology to target NETosis and address difficult to treat cancersStrategic focus on exploratory investigator-initiated clinical studies with institutional partnersContinued progress of DNase I development program towards IND and first-in-human study for treatment of pancreatic carcinoma FRAMINGHAM, MA / ACCESS Newswire / March 19, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) (\"Xenetic\" or the \"Company\"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today reported its financial results for the year ended December 31, 2024.Recent HighlightsExtended its collaborations with the University of Virginia and Scripps Research through 2025;Entered into a Clinical Trial Services Agreement with PeriNess Ltd. to manage investigator initiated exploratory studies of DNase I in combination with chemotherapy and immunotherapy platforms for the treatment of pancreatic carcinoma, colorectal cancer and other locally advanced or metastatic solid tumors; andContinued pursuit of other strategic collaborations to advance the Company's technology.\"Over the course of 2024, our team made notable advancements across multiple fronts. We continued to establish and present a growing body of preclinical data that supports the use of our DNase-based technology across several cancer indications. Additionally, we continued to engage institutional partners to drive our development strategies forward including investigator-initiated studies and partnering on various other efforts. Leveraging these relationships allows us to advance our technology toward the clinic while utilizing our resources efficiently and minimizing our internal investment. Looking ahead to 2025, we are executing on our initiatives as we progress toward an IND and Phase 1 clinical trial and look forward to an exciting year,\" commented James Parslow, Interim Chief Executive Officer and Chief Financial Officer of Xenetic.Xenetic continues to advance its DNase-based technology towards Phase 1 clinical development for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumors. Preliminary preclinical studies evaluating the combinations of DNase I with chemotherapy and DNase I with immuno-therapies in colorectal c...